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This study aimed to assess the clinical impact of 68Ga-DOTATATE and 18F-fluorodeoxyglucose 
with respect to the management plan and to evaluate the prognostic value of both tracers. 
Methods: A total of 104 patients (55 males, 49 females; median age 58 years, range 20–90) with 
histopathologically proven neuroendocrine tumors (NETs) underwent both 68Ga-DOTATATE 
and 18F-FDG PET/CT. Twenty-eight patients (26.9%) had poorly differentiated (PD) and 76 
(73.1%), well-differentiated tumors. PET/CT results and SUVs were compared with prognostic 
factors such as pathologic grading (G1, G2, G3), chromogranin A, and proliferation index 
(Ki67).  
Results: 68Ga-DOTATATE and 18F-FDG PET/CT findings were discordant in 65 (62.5%) and 
concordant in 39 (37.5%) pts. PET/CT results changed the therapeutic plan in 84 (80.8%) pts. In 
22 (21.1%) pts decision making was based on 18F-FDG findings, in 32 (30.8%) on findings with 
both radiotracers, and in 50 (48.1%) on 68Ga-DOTATATE findings. The most frequent 
management decision based on 18F-FDG was initiation of chemotherapy (10 pts, 47.6%). The 
most common treatment decision due to 68Ga-DOTATATE was initiation of peptide receptor 
radionuclide therapy (14 pts, 27.4%). In 11/28 (39.2%) pts with PD NETs the management 
decision was based only on 18F-FDG results. For 68Ga-DOTATATE, SUVmax was higher for G1 
and lower for G3 tumors (p=0.012). However, no significant differences in 18F-FDG-derived 
SUVs were observed between different tumor grades (p=0.38). Mann-Whitney test showed 
significant differences in 68Ga-DOTATATE SUVmax between tumors with Ki<5% and tumors 
with Ki>5% (p=0.004), without significance differences in 18F-FDG SUVmax. Log-rank analysis 
showed statistically significant differences in survival for patients with bone vs soft tissue or no 
metastasis for both 18F-FDG (p=0.037) and 68Ga-DOTATATE (p=0.047). Overall survival was 
found to decline rapidly with increasing histological grade (p=0.001), with estimated survival of 
91 months for G1, 59 months for G2, and 48 months for G3. 
Conclusion: 18F-FDG PET/CT had no clinical impact in G1 NETs and moderate impact in G2 
NETs. However in PD NETs, 18F-FDG PET/CT plays a significant clinical role in combination 
with 68Ga-DOTATATE.  68Ga DOTATATE SUVmax values relate to tumor grade and Ki67 index 




Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies ranging from well-
differentiated, slowly growing tumors to poorly differentiated neoplasms, which are less frequent 
and aggressive 1. Neuroendocrine cells have the ability to express several peptide receptors in 
high volumes, especially somatostatin receptors, which are heptahelical G-protein-coupled 
glycoprotein transmembrane receptors 2. In the past, evaluation of NETs was based mainly on 
somatostatin receptor scintigraphy and other conventional imaging methods such as ultrasound, 
CT, endoscopy, and MRI 3,4; however, following the advent of Postitron Emission 
Tomography/Computed Tomography (PET/CT) systems, novel PET tracers have been developed 
and investigated, including biogenic amine precursors (e.g., fluorine-18 dihydroxyphenylalanine 
[18F-DOPA]), somatostatin analogs (gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
acetic acid [DOTA]), and metabolic markers (18F-FDG) 3.  
Three main DOTA-peptides (DOTATOC, DOTANOC, and DOTATATE) that specifically bind 
to somatostatin receptors overexpressed on the surface of NET cells, allowing visualization of 
NETs, have been used in the clinical setting for either NET diagnosis or peptide receptor 
radionuclide therapy (PRRT) 5,6. PET/CT with 68Ga-DOTA-peptides has been reported to present 
a higher sensitivity for the detection of well-differentiated, less aggressive NETs than CT and 
scintigraphy 7,8. On the other hand, 18F-FDG PET/CT is preferred for more aggressive, less-
differentiated NETs as there is emerging evidence that the presence of increased glucose in 
NETs highlights an increased propensity for invasion and metastasis, and overall poorer 
prognosis 9. In fact, a strong association has recently been shown between high 18F-FDG uptake 
and worse outcome even in patients with well-differentiated or low-grade tumors, with provision 
of prognostic information independently of the mitotic rate 9. Accordingly, 18F-FDG may retain 
an important role in managing patients with NETs owing to its high prognostic value and its 
higher sensitivity in delineating disease extent, especially in aggressive and high-grade tumors 
(4). 
Although the value of PET findings with both 68Ga-DOTA-peptides and 18F-FDG is therefore 
well established, the detection of additional sites of disease is not necessarily associated with 
alteration of therapeutic approach. The aims of this study were to evaluate and compare the 
clinical impact of 68Ga-DOTATATE and 18F-FDG PET/CT on the management plan in patients 
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with NETs and to assess the prognostic value of maximum standardized uptake value (SUVmax) 




 We retrospectively reviewed findings in the first 104 patients (55 male, 49 female, age 
range 20–90 years, median 58 years) with histopathologically proven NETs who underwent 
contemporaneous 68Ga-DOTATATE and 18F-FDG PET/CT at our institution between September 
2006 and February 2014. All patients gave informed consent and institutional board ethics 
approval was received. The interval between the two studies ranged from 0 to 3 weeks (median 1 
week), which was considered sufficiently short given that NETs show relatively slow 
progression.  
All NETs were classified as high, intermediate, or low grade according to the histology reports, 
based on recent consensus statements of the European Neuroendocrine Tumor Society, using 
mitotic index and Ki67 index in staging of NETs along with immunohistochemistry 10 The study 
was approved by the institutional review board (study no. 15N10051) and all subjects signed a 
written informed consent. 
Image acquisition 
 Images were acquired 1 h post injection of 370 MBq 18F-FDG or 45–60 mins after the 
injection of 120–200 MBq 68Ga-DOTATATE. No adverse effects were observed after the 
injection of 68Ga-DOTATATE. Imaging was performed using a dedicated combined GE 
Discovery ST PET/16 detector CT unit (GE Healthcare, Detroit, Mich.); whole-body 
examinations (brain to mid-thigh) were performed with the patient in the supine position. The 
CT exposure factors for all examinations were 120 kVp and 80 mA in 0.8 s. Maintaining patient 
position, a whole-body PET emission scan was performed, covering an area identical to that 
covered by CT. PET acquisition was carried out in 3dimension with 4 min per bed position and 
nine-slice overlap. PET images were reconstructed using CT for attenuation correction. 
Transaxial PET data were reconstructed using ordered subsets expectation maximization with 2 
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iterations and 21 subsets. Transaxial PET slice thickness was 3.27 mm with an in-slice pixel size 
of 4.68 mm. The CT data were reconstructed to axial slices of 3.75 mm and 2.5 mm thickness 
with a soft tissue reconstruction algorithm and 2.5 mm thickness  
Image reporting 
 68Ga-DOTATATE and 18F-FDG PET/CT images were reported in consensus by an 
experienced dedicated nuclear medicine physician and a dual-accredited radiologist/nuclear 
medicine physician. For the evaluation of 68Ga-DOTATATE PET/CT studies, any area with an 
intensity greater than background that could not be identified as physiologic activity (pituitary 
gland, spleen, liver, adrenal glands, head of the pancreas, thyroid, and urinary tract) was 
considered to indicate tumor tissue 6. 68Ga-DOTATATE scans have been performed after 
discontinuation of 72h of short acting SSA and 28days of long acting. The imaging findings of 
the two modalities were compared with each other and with histology. Furthermore, SUVmax 
was calculated by measuring the maximum concentration of the labelled tracer (kBq/ml) in the 
lesion divided by the decay corrected injected activity (kBq) and normalised for body weight. 
  
Clinical impact 
 To evaluate the clinical impact of PET/CT findings, referring physicians were 
subsequently asked to provide information on how patients were managed and how PET/CT 
results had influenced clinical decisions after retrieving all clinical data. Overall impact was 
evaluated patient by patient and was correlated with histopathological findings. In order to 
perform a survival analysis, last date of survival and follow-up were recorded and patients were 
censored regarding whether the cause of death was related to their disease. 
 
Statistical analysis 
 Metric data such as age were expressed as means ± standard deviations. One-way 
ANOVA was used to assess differences in SUVmax across the different histological grades for 
both 68Ga-DOTATATE and 18F-FDG. Mann-Whitney test was used to assess differences in 
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SUVmax between Ki67 (<5%) and Ki67 (>5%) as well as threshold of Ki67 of 12% for both 
68Ga-DOTATATE and 18F-FDG. A p value <0.05 was considered significant. Statistical analysis 
was performed with SPSS software (SPSS Inc., IBM, 22.0, USA).  
Correlation of 68Ga-DOTATATE and FDG SUVmax values with Ki67 index was assessed using 
Spearman’s correlation coefficient. Kaplan-Meier survival analysis was performed to assess the 
prognostic value of 68Ga-DOTATATE and 18F-FDG findings regarding overall survival. To 
assess whether different scan findings related to overall survival, the Kaplan-Meier product limit 
estimators were calculated and compared by log rank tests. Specifically it was tested whether 
soft tissue and bone metastasis results in statistically significant differences in survival. Finally, 
the prognostic value of histological grading and Ki67 index regarding survival was also 





 One hundred and four patients (55 men, 49 women; mean age 58 years, age range 20–90 
years) who underwent 18F-FDG and 68Ga-DOTATATE PET/CT were enrolled in the study. 
Their clinical and epidemiologic characteristics are shown in Table 1. 
Discordant findings 
 68Ga-DOTATATE and 18F-FDG PET/CT findings were discordant in 65 (62.5%) patients 
and concordant in 39 (37.5%). Discordant findings were observed in 25 patients (38.4%) with 
G1 NETs, in 24 (36.9%) with G2 NETs, and 16 (24.7%) with G3 NETs (p>0.05). Only in one 
(2.7%) of 36 patients with G1 tumors (Ki67 index ≤2) (p<0.05) and five (12.5%) of 40 with G2 
tumors (Ki67 index ≤12%) (p<0.05) were 18F-FDG findings more prominent than 68Ga-
DOTATATE findings. However, in all six of these patients the 18F-FDG-avid findings were not 
correlated with NET disease as shown either by biopsy or follow up imaging. The two patients 
with increased metabolic bowel activity had subsequent colonoscopy that showed in one case 
large bowel adenocarcinoma and the second inflammatory changes. The remaining four patients 
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had lung FDG avid abnormalities, all of which benign as confirmed in the follow-up lung CECT. 
Especially in two patients there was a need for follow-up for 12 months to confirm the 
inflammatory pathology. 
Of the 25 patients with discordant results, 22 (88%) with G1 NETs had 68Ga-DOTATATE-
positive findings (p<0.05) and nine (56%) of 16 with G3 NETs had 18F-FDG-positive findings 
(p<0.05), confirming that 68Ga-DOTATATE results are predominant with a lower Ki67 index 
while 18F-FDG results are positive with a higher Ki67 index.  
Clinical impact 
 Considering all cases, the combination of 68Ga-DOTATATE and 18F-FDG PET/CT 
modified therapy in 84 (80.8%) patients. The treatments before the PET/CT scans are listed in 
Table 2. In 22 (21.1%) patients the modification was based on 18F-FDG findings, in 32 (30.8%) 
on findings with both radiotracers, and in 50 (48.1%) on 68Ga-DOTATATE findings (Table 3). 
The most frequent management impact of only 18F-FDG findings was initiation or continuation 
of chemotherapy in ten (47.6%) patients while the second most frequent was surgery in five 
(23.8%) patients, followed by active surveillance. The most common treatment modification due 
to 68Ga-DOTATATE findings was initiation of PRRT in 14 (27.4%) patients, followed by 
commencement of somatostatin analogs in 12 (23.5%). In general there has been change of 
medical treatment in 40 pts (38.5%, confirmation of current treatment in 36pts (34.6%), change 
in surgical planning 15 (14.4%) and cancellation of surgery in 13pts (12.5%).  
Table 4 illustrates the histological NET grading in correlation with the PET/CT tracer with the 
most clinical impact. In 11 of 28 (39.2%) patients with PD NETs the management decision was 
based only on 18F-FDG results. Only in 1 (2.7%) of 36 patients with G1 tumors (Ki67 index 
≤2%) (p=0.001) and 10 (12.5%) of 40 with G2 tumors with a Ki index ≤12% (p=0.003) was the 
management changed owing to the 18F-FDG results. There was no statistically significant 
correlation between presence of chromogranin A in the histological specimen and results with 
either radiotracer (p=0.69 for 68Ga-DOTATATE, p=0.37 for 18F-FDG). Overall, 68Ga-
DOTATATE was more likely to affect the final decision for tumors with low Ki67 expression, 
while 18F-FDG was better in tumors with high Ki67 expression, as demonstrated by Figure 1. 
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Regarding the G2 NET group, we found that in patients with tumors with a Ki67 index ≤12%, 
68Ga-DOTATATE made a greater contribution to clinical management than 18F-FDG. 
Using Kaplan-Meier plots and log-rank comparisons, survival was found to decline rapidly with 
increasing histological grade (p=0.001), with estimated survival of 91 months for G1, 59 months 
for G2, and 48 months for G3.  
Using one-way ANOVA, 68Ga-DOTATATE SUVmax was significantly higher for G1 than for G3 
tumors (p=0.012). However, no significant differences in 18F-FDG-derived SUVmax results 
between tumor grades were detected (p=0.38). As expected, there was a statistically significant 
negative correlation between Ki67 and 68Ga-DOTATATE SUVmax (Spearman rho=-0.374, 
p=0.001). On the other hand, a significant positive correlation was noted between Ki67 and 18F-
FDG SUVmax (rho=-0.345, p=0.002). Further analysis showed significant differences in 68Ga-
DOTATATE SUVmax between tumors with a Ki67 <5% and tumors with a Ki67>5% (p=0.004), 
while no significance difference in 18F-FDG SUVmax values was detected using this cut-off 
value. Interestingly, Mann-Whitney test showed more significant differences in 68Ga-
DOTATATE SUVmax for tumours with a Ki67≤12% and with Ki67>12% (p=0.002) and not for 
18F-FDG SUVmax, indicating that tumours with a Ki67>12% show more aggressive disease 
behaviour. 
Grading patients as zero for no metastasis, 1 for soft tissue metastasis and 2 for bone metastasis, 
log-rank analysis showed statistically significant differences in survival for patients with bone vs 
soft tissue or no metastasis (Figs. 2 and 3). This was true for both 18F-FDG (p=0.037) and 68Ga-
DOTATATE scans (p=0.047), with estimated survival time significantly reduced in patients with 
bone metastasis (48 and 49 months for 68Ga-DOTATATE and 18F-FDG respectively) vs. soft 





 Imaging plays a crucial role in the diagnosis and management of NETs, as after 
histological confirmation of disease, the initial diagnostic work-up and tumor staging form the 
basis for the decision to perform surgical resection or initiate medical therapy. The small size of 
NETs makes it difficult for conventional anatomic imaging to visualize the primary tumor or its 
metastases, given that these modalities are unable to depict specific endocrine features; 
consequently the diagnostic accuracy of functional imaging is significantly higher than that of 
conventional imaging 7,11–14. 
18F-FDG PET/CT imaging has also been compared with 68Ga-DOTA peptide imaging in several 
studies that have shown it to have variable sensitivity in detecting NETs 15–22. However, the 
presence of increased glucose in NETs highlights an increased propensity for invasion and 
metastasis, and 18F-FDG PET/CT accordingly has higher sensitivity in delineating disease extent, 
especially in aggressive and high-grade tumors 23. Detection of a higher number of lesions is 
nevertheless not always followed by a change in disease staging and most importantly does not 
always affect the therapeutic approach. While a number of studies have demonstrated the clinical 
impact of 68Ga-DOTA peptides, few have compared the clinical impact of both PET tracers in 
NET patients 24–27.  
To the best of our knowledge, our study is the first to determine the clinical impact of combined 
68Ga-DOTATATE and 18F-FDG PET/CT in such a large histologically proven NET population 
in correlation with the histological grade. The vast majority of previous studies have compared 
the diagnostic accuracy of both radiotracers, with a relative lack of information regarding the 
influence on treatment approach. 
Our study demonstrates that routine use of both 68Ga-DOTATATE and 18F-FDG PET/CT is not 
recommended for G1 NETs. In this NET subgroup the clinical impact was influenced 
predominately by the 68Ga-DOTATATE study, which we suggest should be performed solely. In 
the G3 NET group the combination of both exams is suggested, with emphasis on the 18F-FDG 
results in patients with higher Ki67 index values, reflecting a high level of glycolytic metabolism 
in high-risk patients with aggressive disease and poorer prognosis in whom chemotherapy is 
favourable 9. However, 68Ga-DOTATATE should also be considered in this subgroup, especially 
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in the event of relapse on chemotherapy regimen, as the somatostatin receptor positivity makes 
PRRT a potential therapeutic option. Jamali et al. have reported that 18F-FDG-positive high-
grade gastroenteropancreatic NET patients have benefited from PRRT 28. Nevertheless, this 
should be proven by a pre- and post-PRRT 68Ga-DOTA-peptide study to delineate better the 
tumor burden and further assess treatment response. 
The current study demonstrates also that 18F-FDG PET/CT has moderate clinical impact in G2 
NETs. We propose that in NET patients with a Ki67 index of ≤12% the use of 18F-FDG PET/CT 
should be limited and tailored to the individual patient, especially when suspicion of a second 
synchronous primary tumor is raised by atypical disease distribution or in cases with previous 
neoplastic process. It should be noted that NETs with a Ki67 index lower than 10% may tend to 
fall in the low-grade category, which may be why they have been reported to have a better 
prognosis 29.  
Strosberg et al. have proposed chemotherapy as an earlier treatment option for tumors with a 
Ki67 higher than 10% following PRRT or somatostatin therapy; such tumors show higher 18F-
FDG activity, reflecting their high proliferative capacity and aggressive behaviour 30. Although 
Ki67 index has been well proven to be correlated with prognostic information in NETs, certain 
aspects of histological staining, such as intratumoral heterogeneity, may rarely cause false 
determination of tumor grade, especially in the G2 category, where the nearly flip-flop 
phenomenon of the dual tracers is more evident 31. Furthermore, the availability of new treatment 
regimens has emphasized the need for new prognostic and predictive biomarkers, leading to 
better assessment of therapeutic response for individual patients 32. Tumor heterogeneity cannot 
be fully assessed by tumor biopsy, and this is an area where combined dual-tracer PET/CT offers 
distinct advantages, even though referring clinicians rely mainly in the histological grading. In 
our population there have been few patients with discrepant lesions, predominantly in the liver, 
with discordant findings between 68Ga-DOTATATE and 18F-FDG PET/CT studies. Biopsy 
from the liver lesions in the same patients showed mildly different Ki67 index (>10% <20%) of 
patients in the G2 category. In such cases we considered as valid the higher Ki67 value, taking 
into consideration the tumour aggressiveness that the metabolic avid tumour provides. 
The clinical impact of 68Ga-DOTANOC and 68Ga-DOTATATE has been well described 
previously. It has been demonstrated that 68Ga-DOTA-peptide imaging influences the 
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management of more than half of patients, with a particular impact on initiation or continuation 
of PRRT or SSA medical therapy on the basis of the demonstration of somatostatin receptor 
expression 24,33,34. Our results similarly show that 68Ga-DOTATATE impacted on the 
management plan in 48% of NET patients. Regarding 18F-FDG, Kayani et al. in a limited cohort, 
concluded that the use of 18F-FDG led to a change from PRRT to chemotherapy in 25% of 
patients with intermediate- or high-grade NETs 15. Our study demonstrated similar results, with 
18F-FDG findings impacting on 21% of patients, half of whom had G3 tumors 30.  
Recent papers investigated the value of 68Ga-DOTANOC SUVmax as a potential prognostic factor 
35–37. We used a cut-off of 5% when relating Ki67 to SUVmax based on the study of Panzuto et al. 
reporting that patients with a Ki67>5% show more aggressive disease behaviour 37. Our data 
validated their findings, with significant differences in 68Ga-DOTATATE SUVmax according to 
whether the Ki67 index was above or below 5%. However we found that there is stronger 
association between aggressive tumour behaviour and functional activity when cutoffs of 
Ki67>12 is implemented.  
The study also showed that SUVmax for 68Ga-DOTATATE is related to NET grade, another 
important prognostic marker. Interestingly there was no relation between FDG SUVmax values 
and tumor grade.  The only report with similar findings was by Sharma et al. in a limited 
population of NET patients with different primary sites 36. In their study, SUVmax for 68Ga-
DOTANOC correlated with prognosis, while 18F-FDG SUVmax did not. Several reports have 
indicated that 18F-FDG positivity is associated with a worse prognosis, although to our 
knowledge most of these studies did not specifically investigate the role of SUVmax 22,38. In our 
study we found that metastases demonstrated by either tracer correlated with shorter survival 
time, with bone metastases correlating with the worst prognosis. 
In regards to the study limitation, the fact that only patients with histologically proven NETs 
were enrolled restricted the possibility of specificity measurement. A second limitation of the 
study includes the histological confirmation from two or more sites of the tumour in patients 
with discrepant findings in both PET/CT tracers. However it would be unethical and not feasible 





 18F-FDG PET/CT has no clinical impact in G1 NETs and moderate impact in G2 NETs. 
In NETs with a Ki67 index ≤12%, use of 18F-FDG PET/CT should be limited and tailored to the 
individual patient. However in PD NETs 18F-FDG PET/CT plays a significant clinical role in 
combination with 68Ga-DOTATATE. 68Ga-DOTATATE SUVmax values are related to tumor 
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FIGURE 1. Correlation between mean Ki67 (%) of NETs and PET/CT tracer results on which 





FIGURE 2: Survival curves for patients with bone (red) vs soft tissue (green) or no metastasis 





FIGURE 3: Survival curves for patients with bone (red) vs soft tissue (green) or no metastasis 




TABLE 1. Patient clinical and epidemiologic characteristics 
 
 n %   n % 
Female 49 47.1  Primary tumor 
site 
33 31.7 
Male 55 52.9  CUP 31 29.8 
Age (years)    Midgut 16 15.4 
Median 58   Lung 11 10.6 
Range 20–90 14.2  Pancreas 5 4.8 
    Stomach 4 3.8 
Indication for 
PET/CT 
   Ovary 3 2.9 
Recurrence 57 54.8  Oesophagus 33 31.7 




13 12.5  Histopathologic 
grade of NETs 
  





10 9.6  G2 moderately 
differentiated 
40 38.5 
Recurrence 57 54.8  G3 poorly 
differentiated 
28 26.9 
       
Ki67 (%)    Chromogranin 
A on histology 
  
Median 6.5   Positive 88 84.6 
Range 1–80 20.2  Negative 13 12.5 
    Positive (weak) 3 2.9 
 
Values are n with percentage or median with IQR 
SD, Standard Deviation; PRRT, Peptide Receptor Radionuclide Therapy; CI, Conventional 




TABLE 2. Treatment before 18F-
FDG and 68Ga-DOTATATE PET/CT  
 No. % 
Surgery 21 20.2 
Active surveillance 20 19.2 
Long Acting SSA 13 12.5 
Short Acting SSA   
Nil 12 11.5 
CMT 11 10.6 




Surgery, Interferon 4 3.8 
Surgery, Y-90, SSA 4 3.8 
PRRT 1 1.0 
Surgery, CMT, SSA, 
TACE, LDT 
1 1.0 
Surgery, RFA 1 1.0 
LDT 1 1.0 
SSA, Somatostatin Analogs; CMT, Chemotherapy; Y-90, 90Y-DOTATATE therapy; PRRT, 
Peptide receptor Radionuclide Therapy; TACE, Transcatheter Arterial Chemoembolization; 
LDT, Liver Directed Therapy; RFA, Radiofrequency Ablation 
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Management post 18F-FDG and 
68Ga-DOTATATE scans 
PET/CT tracer findings on which clinical 
management was based  
Total 
68Ga-
DOTATATE Both 18F-FDG 
 Active surveillance 5 22 4 31 (29.8%) 
Chemotherapy 8 2 10 20 (19.2%)  
Chemotherapy, TACE 0 1 0 1 (1%) 
Everolimus 1 0 0 1 (1%) 
Interferon 0 2 0 2 (1.9%) 
PRRT 14 1 0 15 (14.4%) 
RFA 0 0 1 1 (1%) 
SSA 11 2 2 15 (14.4%) 
Surgery 9 2 5 16 (15.4%) 
LDT 2 0 0 2 (1.9%) 
Total 50 32 22 104 













PET/CT tracer findings on which clinical management 
was based 
Total 68Ga-DOTATATE Both 18F-FDG 
 G1 25 10 1 36 (34.6%) 
G2 16 14 10 40 (38.4%) 
G3 9 8 11 28 (27%) 
Total 50 32 22 104 
